TRT Eligibility 2026: Who Qualifies, Required Labs & the 5 Absolute Contraindications
TRT eligibility in 2026 follows a specific diagnostic pattern that hasn't changed significantly in over a decade: two morning total testosterone readings below the hypogonadism threshold (264-300 ng/dL depending on which guideline your clinician follows), accompanied by documented symptoms of testosterone deficiency. The FDA's March 2025 removal of the 2014 cardiovascular black-box warning didn't loosen the eligibility criteria — it resolved an over-cautious prescribing pattern but the underlying diagnostic framework remains rigorous.
What HAS shifted in 2026 is the access landscape: telehealth platforms (Hims TRT, Hone, Maximus) handle the diagnostic workup async, can arrange labs through partner networks, and prescribe + ship medication directly. The standard of care is the same; the delivery is faster. This guide covers the actual eligibility criteria, the lab and clinical workup required, the five absolute contraindications, and how telehealth vs in-person paths handle the verification step.
The diagnostic criteria for TRT eligibility
Hypogonadism — the clinical condition that justifies TRT — has a specific diagnostic definition. Both the Endocrine Society and the American Urological Association (AUA) publish guidelines used by US clinicians. The key elements:
- Total testosterone below the threshold. Endocrine Society: below 264 ng/dL. AUA: below 300 ng/dL. Both thresholds are based on the lower bound of healthy young-adult male testosterone distributions. Anything in the 264-400 range is a "gray zone" where treatment depends on symptom severity.
- TWO separate morning readings. Blood drawn between 7-10 AM, fasted. Two readings on separate days (often 1-2 weeks apart) confirm the low value isn't due to acute factors (illness, sleep loss, intense exercise, lab variability).
- Documented symptoms. Low libido, erectile dysfunction, fatigue, decreased muscle mass, decreased morning erections, mood changes. Multiple symptoms, not a single complaint.
- Workup of secondary causes. The clinician should rule out reversible causes (medication side effects, sleep apnea, opioid use, severe obesity, recent illness) before committing to TRT, especially in the gray-zone testosterone range.
Insurance coverage in the US generally tracks the AUA threshold (below 300 ng/dL) with documented symptoms. Cash-pay telehealth platforms have more latitude on the interpretation but still require labs + symptoms — no legitimate platform will prescribe testosterone based on symptoms alone.
The 5 absolute contraindications to TRT
Even with biochemical hypogonadism + documented symptoms, certain conditions make TRT inappropriate. The five absolute contraindications:
- Active prostate cancer or breast cancer. Both are testosterone-dependent cancers. Starting TRT in active disease is contraindicated. Patients in remission with appropriate clearance from oncology can sometimes be candidates, but that requires specialty involvement, not standard TRT prescribing.
- Untreated severe sleep apnea. TRT can worsen sleep apnea, and severe sleep apnea also independently suppresses testosterone — treating the apnea first often resolves the low-T finding without TRT. Untreated severe apnea + TRT is a known bad combination.
- Hematocrit above 54%. Polycythemia (elevated red blood cell count) is the most common TRT side effect; starting TRT in already-elevated hematocrit significantly raises stroke and clotting risk. Patients with baseline hematocrit above 54% need workup of the polycythemia before any TRT consideration.
- Uncontrolled severe heart failure. The TRAVERSE trial (NEJM 2023) cleared TRT cardiovascular safety in standard patients, leading to FDA's March 2025 removal of the cardiovascular black-box warning. But severe uncontrolled heart failure remains a contraindication — fluid retention from TRT can worsen heart failure.
- Fertility plans without HCG co-therapy. TRT suppresses pituitary signaling (LH/FSH), which suppresses spermatogenesis. Most TRT patients become functionally infertile within 3-6 months. Patients who want biological children while on TRT need HCG co-therapy from the start; patients who refuse HCG and want to preserve fertility shouldn't start TRT.
Relative contraindications (require careful clinical judgment, not absolute exclusion): untreated benign prostatic hyperplasia (BPH) with severe symptoms; recent (under 6 months) cardiovascular event; BMI above 40 (obesity often suppresses T independently and weight loss may resolve the deficiency); current opioid use (opioids suppress T; discontinuation often resolves the deficiency).
Required baseline labs for TRT
Before any legitimate TRT prescription, the following baseline labs should be drawn:
- Total testosterone (two morning readings) — the foundational diagnostic
- Free testosterone — calculated or directly measured; matters for patients with abnormal SHBG
- Estradiol (sensitive assay) — baseline for monitoring estradiol management on TRT
- Hematocrit / hemoglobin — screens for polycythemia risk
- PSA (prostate-specific antigen) — baseline before TRT; required by standard of care for men over 40
- Lipid panel — baseline for monitoring lipid changes on TRT
- Comprehensive metabolic panel — kidney + liver function
- LH and FSH — distinguishes primary (testicular) from secondary (pituitary) hypogonadism, which affects co-therapy decisions
- SHBG — sex hormone binding globulin; refines free-T interpretation
- Thyroid function (TSH) — rules out hypothyroidism as the symptom cause
Some clinicians order broader panels (DHEA-S, IGF-1, prolactin, ferritin, vitamin D) depending on case complexity. The minimum panel above is what every legitimate TRT provider should run. Specialty TRT clinics (Defy, Marek) typically run 40+ markers at baseline; telehealth bundles (Hims TRT, Hone) typically run 8-12 markers — adequate for straightforward cases.
Telehealth vs in-person verification: state-by-state variation
Federal law treats testosterone as a Schedule III controlled substance. The Ryan Haight Act (2008) generally requires an in-person medical examination before a controlled substance can be prescribed via telehealth — but the COVID-era PHE granted exceptions that have been partially extended through 2025-2026. As of 2026, the practical landscape:
- Most states (40+): Telehealth TRT is legally permissible with appropriate baseline labs (often arranged through partner labs or patient's own lab). Async intake is common; some states require synchronous video for the initial prescribing visit.
- Stricter states (handful): Some states require an in-person physical examination before any controlled-substance prescription, including testosterone. The exact list shifts; major telehealth platforms (Hims TRT, Hone) handle state checks during the intake and will route you to in-person care if your state requires it.
- State medical board variation: Beyond the Ryan Haight federal floor, individual state medical boards have additional rules (e.g., follow-up cadence requirements, lab monitoring frequency requirements, controlled-substance prescription duration limits).
Practical implication: the major telehealth TRT platforms have legal teams that handle state-specific compliance. If your state allows telehealth TRT, the platforms will serve you; if it doesn't, the intake will route you to in-person care or decline. For patients in stricter states, specialty TRT clinics (Defy in Florida, Marek multi-state) often have established in-person + telehealth hybrid pathways.
TRT eligibility in 2026 is the same rigorous diagnostic framework it was in 2020 — what changed is the access landscape, not the criteria. Two morning labs below threshold plus documented symptoms is non-negotiable; any provider that skips this is outside standard of care.
Frequently asked questions
What's the testosterone level cutoff for TRT eligibility?
Most US clinical guidelines define hypogonadism as total testosterone below 264-300 ng/dL (Endocrine Society uses 264; AUA uses 300) on TWO separate morning blood draws (between 7-10 AM, fasted), accompanied by documented symptoms. A single low reading is not sufficient for diagnosis. Some clinicians use the 'low-normal' band (300-400 ng/dL) plus strong symptoms to justify therapy, but that's a clinical judgment call, not a clear guideline-driven indication.
Why are TWO morning testosterone readings required?
Testosterone has substantial diurnal variation (peaks in early morning, drops 30-50% by evening) and day-to-day variation (10-25% between consecutive days). A single reading can be misleadingly low due to acute illness, sleep deprivation, recent intense exercise, or simple lab variability. Two morning readings on separate days establish that the low value is the steady-state, not noise. Skipping the second reading is a red flag for any TRT provider — that's not legitimate diagnostic care.
What symptoms qualify alongside the lab number?
Documented symptoms of testosterone deficiency: low libido (most-cited), erectile dysfunction, fatigue, decreased muscle mass / strength, increased body fat, depressed mood, brain fog, decreased morning erections, hot flashes (rare in men but documented), and decreased bone density. The patient should have multiple symptoms — a single symptom plus borderline labs is typically not sufficient for legitimate TRT prescribing.
What are the absolute contraindications to TRT?
Five absolute contraindications: (1) active prostate cancer or breast cancer, (2) untreated severe sleep apnea, (3) hematocrit above 54% (significant polycythemia risk), (4) uncontrolled severe heart failure, (5) desire for biologic fatherhood without HCG co-therapy (TRT suppresses sperm production). The first three are universal; the fourth requires careful cardiac evaluation; the fifth is a fertility consideration that some patients accept and others manage with HCG.
Can I get TRT through telehealth, or do I need in-person?
Most US states allow telehealth TRT prescribing as long as appropriate baseline labs are obtained (sometimes through a partner lab the telehealth provider arranges, sometimes through your own lab). A few states require an in-person physical examination before initial prescription of controlled substances; testosterone is Schedule III, so this rule applies. Your state of residence determines which path is available. Most major telehealth TRT platforms (Hims TRT, Hone, Maximus, Marek, Defy) handle the state-specific requirements within their intake.
What if my testosterone is in the 'low-normal' range (300-400 ng/dL)?
This is the gray zone. Endocrine Society guidelines say below 264 ng/dL is hypogonadism; AUA says below 300; clinically many providers will treat patients with strong symptoms in the 300-400 range. Insurance coverage usually requires labs below 300 ng/dL plus documented symptoms. Cash-pay telehealth platforms have more latitude on the gray-zone treatment. If your levels are 300-400 and you have strong symptoms, multiple opinions are reasonable — and a sleep study or other workup to rule out reversible causes is appropriate before TRT.
Should I trust a provider that prescribes TRT without baseline labs?
No. Any legitimate TRT provider requires baseline labs before prescribing — typically: total testosterone (morning, two readings), free testosterone, estradiol (sensitive assay), hematocrit, PSA, lipid panel, and often comprehensive metabolic panel + thyroid. A provider that prescribes testosterone without baseline labs is operating outside standard of care. This applies to telehealth and in-person equally. If you're being prescribed without bloodwork, find another provider — not because the provider is necessarily unsafe, but because you cannot safely stay on TRT without baseline + ongoing monitoring.